Aiforia, a software company providing pathologists with AI-based solutions for clinical diagnostics and preclinical analysis, today announced that Marco Comianos has joined the company as VP of Sales, Americas. Comianos will oversee sales efforts, as well as driving new business, revenue growth, and more partnerships with top hospitals and pharma companies across the region.
Over 3,000 users in over 50 countries are active users of Aiforia’s cloud software and services for tissue-based research and diagnostics. A significant proportion of these collaborators and customers are based in North America — including one of the top ranked hospitals in the world, the Mayo Clinic, and some of the world’s largest pharmaceutical organizations such as Boehringer Ingelheim.
Comianos joins Aiforia from Flywheel.io, a medical technology company also offering cloud-based medical image analysis solutions for preclinical and clinical research where he built and oversaw the sales organization, its processes, and drove revenue growth as VP of Sales. He has over 20 years of experience in sales in the healthcare industry, including roles at GE Healthcare and Siemens Healthcare.
“Marco’s considerable experience in leading sales teams and his background in B2B sales of software and technology products in the healthcare industry will be instrumental in helping us achieve our growth targets in North America,” explains Jukka Tapaninen, CEO of Aiforia Technologies Plc.
Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more: www.aiforia.com
Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33610416686
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878
UB Securities Ltd, tel. +358405886769